Preclinical data involving GBM animal models imply that the efficiency of PARP inhibitors in GBM could be restricted because of limited transport over the BBB membrane and heterogeneous glioma response (Gupta et al., 2014; Kizilbash et al., 2017; Parrish et al., 2015; Gupta et al., 2016). Here, PARP1 is linked to glioma.